Articles
The outlook for HIV drug development

The outlook for HIV drug development

The HIV market is shifting towards integrase inhibitor-based single-tablet regimens – but emerging markets such as Brazil and China are hesitant to pay the cost.

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D